HOME > TOP STORIES

TOP STORIES

REGULATORY MHLW to Announce Data Required for Conditional Early Approval

July 12, 2017
ACADEMIA New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment

July 11, 2017
BUSINESS Chugai, Osaka Univ. Immunology Collaboration Gets Underway

July 11, 2017
BUSINESS Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact

July 10, 2017
BUSINESS RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO

July 10, 2017
BUSINESS AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race

July 7, 2017
BUSINESS Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations

July 6, 2017
REGULATORY Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments

July 6, 2017
BUSINESS Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen

July 5, 2017
BUSINESS Delving into Securities Filings - Part 1: 27 Drug Makers’ Workforce Down 0.5% as Major Firms Continue to Shed Jobs

July 4, 2017
BUSINESS Ex-JPMA Chief Aoki Wants to See Japan’s Gilead, Govt Leadership in Consolidation

July 3, 2017
REGULATORY MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines

June 30, 2017
REGULATORY “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo

June 29, 2017
REGULATORY Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method

June 29, 2017
BUSINESS Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec

June 28, 2017
BUSINESS Pfizer Japan Ups Oncology Sales Force, Reorganizes It into Blood, Solid Cancer Groups

June 27, 2017
BUSINESS Sumitomo Dainippon’s Napabucasin Stumbles on PIII Gastric Cancer Study

June 27, 2017
BUSINESS Daiichi Sankyo Confident of Achieving US$1 Billion Sales for Edoxaban

June 26, 2017
REGULATORY Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns

June 23, 2017
BUSINESS Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?

June 22, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…